Published in Health and Medicine Week, September 4th, 2006
On June 12, 2006, the company announced that it had met with the U.S. Food and Drug Administration (FDA) to discuss the results of MIRA-1, the company's recently completed clinical trial of its RHEOTM System to treat the dry form of age-related macular degeneration, and confirmed that the FDA will require the company to perform an additional study of the RHEOTM System.
In accordance with Statement of Financial Accounting Standards No. 142, "Goodwill and Other...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.